Abstract: The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.

Abstract: The present invention provides a robust single clone Master Cell Bank (MCB) for an optimized production of H-1 parvovirus (H-1 PV) which is suitable to increase infectious parvovirus production compared to standard producer NB-324K mixed cells.

Abstract: Described is a parvovirus formulation which comprises (a) at least 1×109 pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus such as LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus or Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl2×2 H2O, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium. A preferred use is the therapy of a brain tumour by intratumoral injection.

Abstract: The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.

Abstract: The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.

Abstract: Described is a pharmaceutical composition comprising (a) a parvovirus and (b) bevacizumab and the use of said composition for treatment of cancer, e.g., a solid tumor.

Abstract: Described is a pharmaceutical composition comprising (a) a parvovirus and (b) bevacizumab and the use of said composition for treatment of cancer, e.g., a solid tumor.

Abstract: Described is a parvovirus formulation which comprises (a) at least 1×109 pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus such as LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus or Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl2×2 H2O, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium. A preferred use is the therapy of a brain tumour by intratumoral injection.

Abstract: Described is a parvovirus formulation which comprises (a) at least 1×109 pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus such as LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus or Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl2×2 H2O, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium. A preferred use is the therapy of a brain tumour by intratumoral injection.

Abstract: The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.

Abstract: Described is a parvovirus formulation which comprises (a) at least 1×109 pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus such as LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus or Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl2 x 2 H2O, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium.. A preferred use is the therapy of a brain tumour by intratumoral injection.

Abstract: Described is a pharmaceutical composition comprising (a) a parvovirus and (b) bevacizumab and the use of said composition for treatment of cancer, e.g., a solid tumor.

Abstract: The invention relates to a method of preparing an original sample (3) of biological origin with a view to detecting at least one component contained in it, whereby the original sample (3) is enclosed in a first container (1) and at least a part of this original sample (3) is transferred from the first container (1) into at least one reaction container, a reagent (9) or reagent mixture being placed beforehand in at least one of the reaction containers in order to prepare the original sample (3) and the component to be detected. In order to transfer at least a part of the original sample (3), two respective containers (1, 6) are connected to one another to form a closed, airtight system at least until at least the component(s) to be detected has (have) been rendered stable by reacting it (them) with the reagent (9) or reagent mixture at room temperature.

Abstract: A method for manufacturing a reflector (5) for X-ray radiation (2, 3, 10, 11) which is curved in a non-circular arc shape, along a first cross-section (13) in a plane (XZ) which contains a x-direction, wherein the reflector (5) is also curved along a second cross-section (14) in a plane (YZ) which is perpendicular to the x-direction, is characterized in that the reflector (5) has a curvature along the second cross-section (14) which also differs from the shape of a circular arc. This makes the design of X-ray mirrors and the beam profile of reflected X-ray radiation more flexible, facilitates production of X-ray mirrors and at the same time provides high reflection capacity and good focusing properties for X-ray mirrors.

Abstract: Mapping of data source schema data types relating a server side database description into a set of OLE DB data types is rendered subject to user modification by provision of a dual Schema File at a client side terminal which contains an original copy and a modifiable copy of the data source schema. Selected contents of the modifiable Schema File are then displayed in a split window format, including one window which provides a tree view of the schema structure and an adjacent window which displays a set of values related to a selected element of the tree view. Selected values are then subject to modification via user point and click and data entry operations.

Abstract: The invention relates to a method for selecting a partial sequence from a nucleic acid sequence whose similarity to a given total sequence is as low as possible. More specifically, the invention relates to a method for selecting partial sequences of a given nucleic acid sequence, which are suitable for hybridization and, owing to their low similarity to said total sequence, can be used for detecting said given nucleic acid sequence.

Abstract: A method for manufacturing a reflector (5) for X-ray radiation (2, 3, 10, 11) which is curved in a non-circular arc shape, along a first cross-section (13) in a plane (XZ) which contains a x-direction, wherein the reflector (5) is also curved along a second cross-section (14) in a plane (YZ) which is perpendicular to the x-direction, is characterized in that the reflector (5) has a curvature along the second cross-section (14) which also differs from the shape of a circular arc. This makes the design of X-ray mirrors and the beam profile of reflected X-ray radiation more flexible, facilitates production of X-ray mirrors and at the same time provides high reflection capacity and good focusing properties for X-ray mirrors.

Abstract: Mapping of data source schema data types relating a server side database description into a set of OLE DB data types is rendered subject to user modification by provision of a dual Schema File at a client side terminal which contains an original unmodifiable copy and a modifiable working copy of the data source schema. When the server side database description is altered, user modifications to the modifiable copy are preserved as much as possible by performing a matching process on the client side in the course of generating new unmodifiable and modifiable schema files which comprise a new dual Schema File.

Abstract: The invention relates to a method for enriching tumor cells from a body fluid, in which a cell separation medium of a specific density is overlaid with the body fluid and it is subsequently determined whether the enriched cells express an epithelial marker, for example a cytokeratin. A kit suitable for this method is likewise provided.

Abstract: The invention relates to a method of preparing an original sample (3) of biological origin with a view to detecting at least one component contained in it, whereby the original sample (3) is enclosed in a first container (1) and at least a part of this original sample (3) is transferred from the first container (1) into at least one reaction container, a reagent (9) or reagent mixture being placed beforehand in at least one of the reaction containers in order to prepare the original sample (3) and the component to be detected. In order to transfer at least a part of the original sample (3), two respective containers (1, 6) are connected to one another to form a closed, airtight system at least until at least the component(s) to be detected has (have) been rendered stable by reacting it (them) with the reagent (9) or reagent mixture at room temperature.